Eurofins Announces the Launch of the Largest European Biomonitoring Project for PFAS in Blood in Antwerp, Belgium
October 03 2022 - 12:30AM
Business Wire
Regulatory News:
Eurofins Scientific (EUFI.PA) (Paris:ERF), the global leader in
environmental testing and a global scientific leader in
bioanalytical testing, announces the commencement of the largest
European biomonitoring project for PFAS in blood in Antwerp,
commissioned by the Agency for Care and Health of the Flemish
Government. The biomonitoring testing for this project will be
carried out by Eurofins Belgium NV.
PFAS, per and polyfluoroalkyl substances, are a class of over
4,700 synthetic chemicals with unique characteristics that can be
used to make products heat and stain resistant, non-stick and water
repellent. Sometimes referred to as ‘forever chemicals’ PFAS are
very stable compounds that are largely unsusceptible to degradation
and accumulate and persist in the environment. Accumulation of PFAS
in blood has been linked to a number of health risks.
In June 2022, 70,000 inhabitants in a 5km zone around the 3M
factory in Antwerp, Belgium were invited to participate in a
biomonitoring project to assess whether PFAS is present in their
blood. In the coming days an additional 22,000 inhabitants of the
city of Antwerp will receive an invitation to participate.
Currently 7,450 people have subscribed to the project, and
registration will be open to participants until 1 June 2023 at
https://www.vlaanderen.be/pfas-vervuiling/zwijndrecht/pfas-bloedonderzoek.
All participants will receive results indicating the level of PFAS
present in their blood within 14 working days.
This research project is fully funded by the Flemish Government
and PFAS testing is made available to all participants for free.
The goal of this project is to provide participants with
information about their own personal exposure to PFAS. Data
collected from the study will also provide insights to inform
recommendations and decision making in relation to how human PFAS
exposure can be limited in the future, both in Belgium and further
afield.
Project kick-off will commence in October 2022 with Eurofins
Labo Van Poucke beginning to take blood samples at the beginning of
2023 at a number of locations close to participants. Blood sampling
will be carried out through the traditional venous method and/or
via capillary blood sampling (finger prick) utilising Eurofins
empowerDX test kits. Eurofins Belgium NV and the Agency for Care
and Health of the Flemish Government are aiming to maximise
participation levels in order to generate useful and representative
data and insights. The findings of the biomonitoring study will be
ultimately presented by June 2025.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. Eurofins is the global leader in
food, environment, pharmaceutical and cosmetic product testing, and
in discovery pharmacology, forensics, advanced material sciences
and agroscience Contract Research services. Eurofins is also a
market leader in certain testing and laboratory services for
genomics, and in the support of clinical studies, as well as in
BioPharma Contract Development and Manufacturing. The Group also
has a rapidly developing presence in highly specialised and
molecular clinical diagnostic testing and in-vitro diagnostic
products.
With over 61,000 staff across a decentralised and
entrepreneurial network of 940 laboratories in 59 countries,
Eurofins offers a portfolio of over 200,000 analytical methods to
evaluate the safety, identity, composition, authenticity, origin,
traceability and purity of a wide range of products, as well as
providing innovative clinical diagnostic testing services and
in-vitro diagnostic products.
The Group’s objective is to provide its customers with
high-quality services, innovative solutions and accurate results on
time. Eurofins is ideally positioned to support its clients’
increasingly stringent quality and safety standards and the
increasing demands of regulatory authorities as well as the
requirements of healthcare practitioners around the world.
In 2020 and 2021, Eurofins reacted quickly to meet the global
challenge of COVID-19, by creating the capacity to help over 20
million patients monthly who may have been impacted by the pandemic
with our testing products and our services and directly supporting
healthcare professionals working on the front line to fight the
virus. The Group has established widespread PCR testing
capabilities and has carried out over 40 million tests in its own
laboratories, is supporting the development of a number of vaccines
and has established its SAFER@WORK™ testing, monitoring and
consulting programmes to help ensure safer environments, travel and
events during COVID-19.
Eurofins has grown very strongly since its inception and its
strategy is to continue expanding its technology portfolio and its
geographic reach. Through R&D and acquisitions, the Group draws
on the latest developments in the field of biotechnology and
analytical chemistry to offer its clients unique analytical
solutions.
Shares in Eurofins Scientific are listed on the Euronext Paris
Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF
FP).
Until it has been lawfully made public widely by Eurofins
through approved distribution channels, this document contains
inside information for the purpose of Regulation (EU) 596/2014 of
the European Parliament and of the Council of 16 April 2014 on
market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific’s management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantees can be made as to their completeness
or validity.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221002005014/en/
For more information, please visit www.eurofins.com or
contact: Investor Relations Eurofins Scientific SE Phone: +32 2
766 1620 E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024